{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Adverum Biotechnologies, Inc."},"Symbol":{"label":"Symbol","value":"ADVM"},"Address":{"label":"Address","value":"800 SAGINAW DRIVE, REDWOOD CITY, California, 94063, United States"},"Phone":{"label":"Phone","value":"+1 650 659-9323"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections."},"CompanyUrl":{"label":"Company Url","value":"https://www.adverum.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bill Tan","title":"SVP & Head-Global Clinical Operations"},{"name":"Kalliopi Stasi","title":"Senior Vice President-Clinical Development"},{"name":"Laurent Fischer","title":"President, Chief Executive Officer & Director"},{"name":"Peter Soparkar","title":"Chief Operating & Legal Officer"},{"name":"R. Andrew Ramelmeier","title":"Chief Technology Officer"},{"name":"Rabia Gurses Ozden","title":"Chief Medical Officer"},{"name":"Romuald Corbau","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}